Shield Therapeutics has raised funds
Shield Therapeutics Plc has completed a placing, subscription and open offer. The primary use of the funds is to launch Accrufer® in the USA.
Shield is a de-risked, specialty pharmaceutical company focused on commercializing its lead product, Feraccru®/Accrufer®, a novel, non-salt-based oral therapy for adults with iron deficiency with or without anemia.
Oaklins Cavendish’s sister firm finnCap, based in the UK, acted as the joint broker on this transaction.
Talk to the deal team
PartnerLondon, United Kingdom
Alexandria Pankkiiriliike Oyj has raised US$9.7m in the course of its IPO on NASDAQ First North Finland
Alexandria Pankkiiriliike Oyj (Alexandria) has raised US$9.7 million in the course of its IPO.Learn more
Gilde Healthcare has invested in Tandarts Today
Gilde Healthcare has invested in Tandarts Today, a fast-growing dental chain in the Netherlands. The investment will allow Tandarts Today to accelerate its buy-and-build strategy and become a leading dental chain in the Netherlands. Financial details have not been disclosed.Learn more
Avantium has raised US$33.6m via an accelerated bookbuild offering
Avantium N.V. has raised US$33.6 million through an accelerated bookbuild offering of 5,206,589 new ordinary shares, representing approximately 19.99% of the company’s issued share capital. The shares have been placed at a price of US$6.42 (€5.35) per new ordinary share.Learn more